In a nutshell This study looked at using both chemotherapy and blinatumomab (Blincyto) prior to stem cell transplant (SCT) for patients with relapsed or unresponsive aggressive non-Hodgkin lymphoma (NHL). It found that blinatumomab is an effective second salvage for patients who did not fully respond to chemotherapy. Some background NHL is a...
Read More
In a nutshell The study evaluated the contribution of chemotherapy on cancer-related cognitive impairment (CRCI) reported by women with early breast cancer. The authors found that chemotherapy added to hormonal therapy caused early and short-term CRCI in such patients, compared to hormonal therapy alone. Some background CRCI refers to problems in...
Read More
In a nutshell This study examined if radiotherapy (RT) would benefit patients with advanced Hodgkin lymphoma (HL) with small tumors following chemotherapy. The authors found that RT may increase patients’ survival without worsening of HL, although this may also increase side effects. Some background Treatment options for patients with...
Read MoreIn a nutshell This study evaluated the safety and effectiveness of an experimental treatment, lurbinectedin, in patients with small-cell lung cancer (SCLC) after unsuccessful treatment with platinum-based chemotherapy. The authors found that this treatment showed promising effectiveness and manageable side effects in these...
Read MoreIn a nutshell This study evaluated the outcomes of vaccination in children with acute lymphoblastic leukemia (ALL). This study found that children had less vaccine protection after chemotherapy. Some background Vaccines help the immune system recognize a pathogen using dead or weakened bacteria or viruses. Vaccines are not effective if someone’s...
Read MoreIn a nutshell This study looked at combining chemotherapy with dasatinib (Sprycel) to treat patients with acute myeloid leukemia (AML) with a CBF mutation. This study found that dasatinib was a safe and effective treatment for these patients. Some background AML is a cancer of immature blood cells called myeloid cells. Around 12% of AML cases...
Read MoreIn a nutshell This study evaluated whether the risk and severity of asparaginase-associated pancreatitis (AAP) depend on the age of patients with acute lymphoblastic leukemia (ALL). The main finding was that the AAP risk was higher in adolescents and adults compared to younger children. Some background Asparaginase (ASP; Oncaspar) is an important...
Read MoreIn a nutshell This study evaluated the safety and effectiveness of ESHAOx chemotherapy for patients with Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. This study found that this regimen is effective, with manageable side effects. Some background Most patients with HL respond well to initial treatment. However, some...
Read MoreIn a nutshell This study compared the effectiveness and safety of acalabrutinib (Calquence) to other targeted therapies for patients with mantle cell lymphoma (MCL). The authors found that acalabrutinib was just as safe and more effective for these patients. Some background MCL is a type of non-Hodgkin's lymphoma treated in...
Read MoreIn a nutshell This study investigated the role of oxaliplatin (Eloxatin) in treating patients with rectal cancer after surgery. Researchers suggested that this drug may be a good option in the treatment of rectal cancer. Some background Chemotherapy is one of the standard treatments for rectal cancer. It usually consists of...
Read MoreIn a nutshell This study compared different treatment combinations for first-line and maintenance therapies in elderly patients with multiple myeloma (MM). The authors found that first-line MPR was most effective for fit elderly patients, while all patients benefitted from RP maintenance therapy. Some background MM is a complex disease, and...
Read MoreIn a nutshell This study evaluated camrelizumab (SHR 1210) for patients with classical Hodgkin's Lymphoma (cHL) that has come back or is resisting treatment. The authors concluded that this drug is a safe and effective treatment for these patients. Some background After initial treatment, 5-10% of patients with cHL do not...
Read More
